Interactions between tumors and host tissues play essential roles in tumor-induced systemic wasting and cancer cachexia, including muscle wasting and lipid loss. However, the pathogenic molecular mechanisms of wasting are still poorly understood. Using a fly model of tumor-induced organ wasting, we observed aberrant MEK activation in both tumors and host tissues of flies bearing gut-yki 3SA tumors. We found that host MEK activation results in muscle wasting and lipid loss, while tumor MEK activation is required for tumor growth. Strikingly, host MEK suppression alone is sufficient to abolish the wasting phenotypes without affecting tumor growth. We further uncovered that yki 3SA tumors produce the vein (vn) ligand to trigger autonomous Egfr/MEK-induced tumor growth and produce the PDGF-and VEGF-related factor 1 (Pvf1) ligand to non-autonomously activate host Pvr/MEK signaling and wasting. Altogether, our results demonstrate the essential roles and molecular mechanisms of differential MEK activation in tumor-induced host wasting.
In Brief
Mechanisms of tumor-induced host wasting are largely unknown. Song et al. provide evidence that tumor-derived ligands trigger tumor growth and host wasting via differential MEK activation. They demonstrate that yki 3SA -gut tumors produce vn and Pvf1 ligands to trigger MEK-associated tumor growth and host wasting, respectively.
INTRODUCTION
Many patients with advanced cancer exhibit a systemic wasting syndrome, referred to as ''cancer cachexia,'' with major features of progressive loss of muscle and adipose tissues. Cachexia is associated with poor chemotherapy response, reduced life quality, and increased mortality (Fearon et al., 2013) . Unlike malnutrition conditions, cachexia can rarely be reversed by nutritional supplementation and is frequently accompanied with hyperglycemia (Chevalier and Farsijani, 2014) . A number of findings in cultured cells have indicated that in addition to systemic inflammatory responses, tumors produce secreted factors (e.g., interleukins and activins) that directly target myotubes and adipocytes to cause myotube wasting and lipid loss, respectively (Miyamoto et al., 2016) . Antibody neutralization of tumor-derived cachectic ligands (PTHrP) also significantly improves host wasting (Kir et al., 2014) . Despite these advances, genetic animal models to comprehensively assess tumor-secreted ligands, the signaling pathways they regulate, and their effects in various tissues are far less established. The adult Drosophila midgut has emerged as a model system to study tumorigenesis. Many mutations involved in human cancer have been found to result in overproliferation of fly intestinal stem cells (ISCs) and tumor formation (Patel and Edgar, 2014) . The fly midgut has also been established as a conserved genetic model to study tumor-induced host wasting. We found that induction of an active oncogene yorkie (yki 3SA ), the homolog of human Yap1, that causes gut tumor formation is associated with organ wasting phenotypes, including muscle dysfunction, lipid loss, and hyperglycemia. Mechanisms included that yki 3SA -gut tumors produce the IGF-antagonizing peptide ImpL2 that suppresses systemic insulin signaling and anabolism and contributes to host wasting (Kwon et al., 2015) . In addition, ImpL2 regulation of host wasting has also been observed in transplanted tumors that are generated from fly imaginal discs (Figueroa-Clarevega and Bilder, 2015) . Together, these findings emphasize that communication between tumor and host organs is a general phenomenon, and that Drosophila can be used to dissect the molecular mechanisms involved in tumor-host interaction. The MEK/ERK cascade is a highly conserved mitogen-activated protein kinase (MAPK) pathway involved in various biological regulations in both fly and mammals (Friedman and Perrimon, 2006) . MEK signaling, in addition to controlling cell proliferation, promotes muscle atrophy via modulation of ubiquitin-dependent protein degradation and enhances lipid mobilization via modulating GPCR/cAMP cascade (Hong et al., 2018; Zheng et al., 2010) . These results indicate that MEK signaling is associated with loss of muscle and adipose tissues, the main features of cancer cachexia, and suggest that MEK activation may be involved in tumor-induced host wasting. However, administration of MEK inhibitors in tumorbearing mice and patients are associated with inconsistent results (Au et al., 2016; Prado et al., 2012; Quan-Jun et al., 2017) .
In this study, we revealed aberrant MEK activation in both tumors and host tissues (muscle and fat body) of flies bearing yki 3SA -gut tumors. In the context of gut-tumor growth, pharmaceutical inhibition of MEK signaling in the host tissues alone is sufficient to alleviate host wasting, including muscle wasting, lipid loss, hyperglycemia, and elevated mortality, in tumorbearing flies. Integrating RNA sequencing (RNA-seq) and RNA interference (RNAi) screening, we demonstrate that yki 3SA -gut tumors produce the Pvf1 ligand to activate MEK signaling and enhance catabolism in host tissues. yki 3SA -gut tumors also produce the vn ligand to autonomously promote MEK signaling and self-growth.
RESULTS
MEK Activation in yki 3SA -Tumor-Bearing Flies
Contributes to Wasting of Host Tissues
To analyze the role of MEK/ERK signaling in tumor-host interaction, we first examined whether MEK signaling is activated in host tissues during tumor-induced wasting. We expressed an activated form of yorkie (yki 3SA , yki S111A-S168A-S250A triple mutant) in adult ISCs using the temperature-sensitive GAL4 driver to trigger the development of GFP-labeled gut tumors (esg-GAL4, (Slack et al., 2015) . We initially fed flies normal food containing 10 mM or 100 mM Tram at tumor initiation (day 0). Both doses resulted in the strong MEK suppression in host tissues and diminished the bloating or wasting phenotypes of yki
3SA
-tumor-bearing flies at day 8 (Figures 2A and  2B ). However, we observed a strong reduction of yki 3SA -tumor growth in the midgut (Figure 2A ), suggesting that MEK activation is crucial for yki 3SA -tumor growth. Consistently, we observed a robust increase of pdERK in yki 3SA -tumor gut cells ( Figure 2C ). Specific dERK knockdown in yki 3SA tumors was sufficient to terminate tumor growth ( Figure 2D and S1J-S1K (Figure S1I ). Similar to wasting-associated mortality of cancer patients (Fearon et al., 2013) , yki 3SA -tumor-bearing flies also exhibited a shortened lifespan, while it was surprisingly extended by 1 and 10 mM Tram (Figures S2L-S2M ). Note that feeding 1 mM Tram did not affect yki 3SA -tumor growth even at day 30 when most yki 3SA -tumor-bearing flies died ( Figure S2N 
MEK Activation Contributes to LLC-Induced Wasting of Adipocytes and Myotubes
We next tested whether the similar effects of MEK activation could be observed in mammalian wasting models. Conditioned medium from mouse LLC (Lewis lung carcinoma) cancer cells strongly induces lipid loss in adipocytes and myotube atrophy (Rohm et al., 2016; Zhang et al., 2017) . We found that LLC-conditioned medium activates MEK signaling in both cultured C2C12 myotubes and 3T3-L1 adipocytes after 15 min treatment ( Fig level, and atrophy phenotype in C2C12 myotubes (Liu et al., 2011; Zheng et al., 2010) (Figures S4A-S4E) . Similarly, LLCconditioned medium potently enhanced, while adding Tram significantly hampered, lipolysis rate and TAG decline in differentiated 3T3-L1 adipocytes (Figures S4F-S4I) . Thus, our results demonstrate that MEK activation also causes tumor-induced wasting in mammalian myotubes and adipocytes.
Using RNA-Seq and RNAi Screening to Identify yki 3SA -Tumor-Derived Cachectic Ligands
We hypothesized that MEK non-autonomous regulation of host wasting is caused by secreted proteins from yki 3SA -gut tumors. To identify such factors, we characterized the transcriptomic changes in yki 3SA -tumor midguts using RNA-seq. Following statistical analysis, 2,211 genes were found to be significantly changed (fold change > 2) encompassing 1,659 up-and 552 down-regulated genes in yki 3SA midguts ( Figure 3A ; Table S1 ).
Among the 794 genes encoding secreted proteins annotated by GLAD Gene Ontology , 92 were significantly up-regulated and 36 were down-regulated (Table S1 ). Genes encoding different trypsins were the most differentially regulated in yki 3SA -tumor guts ( Figure S3F , up). As flies bearing yki 3SA tumors did not exhibit a digestion or absorption problem (Kwon et al., 2015) , we speculate that yki 3SA tumors only change the composition of trypsin production but do not affect trypsin-associated nutrient absorption in the gut. Interestingly, the transcriptional levels of gut hormones, which are produced in enteroendocrine cells (EEs) (Reiher et al., 2011; Song et al., 2017a; Song et al., 2014) , were decreased in yki 3SA midguts ( Figure S3F , down). Immunostainings also revealed that EEs (Pros + cells) were largely missing in yki 3SA midguts ( Figure S3G ). We next asked whether yki 3SA -gut tumors cause host wasting via loss of EEs and gut hormones, and overexpressed an active form of Notch (N act ) in
ISCs to genetically suppress EE generation in the midgut (Takashima et al., 2011) . Consistently, ISC overexpression of N act potently eliminated EEs in the midgut ( Figure S3G ) but failed to affect bloating/wasting effects ( Figure S3H ). N act overexpression slightly reduced survival rates of flies ( Figure S3I ), but the extent of decline was very marginal as compared to yki 3SA -tumorbearing flies. We next hypothesized that yki 3SA -gut tumors cause host wasting via increasing the production of a cachectic ligand(s) such as ImpL2. We thus performed an RNAi screening of most up-regulated ligand-encoding genes in yki 3SA tumors ( Figure 3B ).
Interestingly, knockdown of 39 ligand-encoding genes (60 RNAi lines) in yki 3SA -gut tumors still exhibited both tumor growth and abdomen bloating. However, knockdown of 17 ligand-encoding genes (24 RNAi lines) in yki 3SA -gut tumors (referred to as Group ''Tumor without Bloating'') diminished bloating without affecting tumor growth, suggesting that these ligands regulate tumorinduced wasting. Knockdown of 8 genes (11 RNAi lines) (referred to as Group ''Non-tumor'') exhibited no tumor growth, suggesting that these ligands are essential for yki-induced tumorigenesis ( Figure 3C ; Table S2 ). Figure 3G ) and found that Pvf1 knockdown in yki 3SA tumors suppressed pdERK levels significantly in the fat body and moderately in muscles and subsequently improved systemic wasting, including TAG decline, trehalose elevation, and muscle defects, in tumorbearing flies ( Figures 3H-3K ). We also generated yki 3SA -tumors in Pvf1-null mutant flies (Wu et al., 2009 ) and confirmed that systemic removal of Pvf1 also significantly alleviated the wasting effects in host tissues without perturbing yki
3SA
-tumor growth ( Figures 3M and 3N ). Despite restoration of host wasting, Pvf1 knockdown in yki 3SA tumors failed to extend longevity of tumor-bearing flies ( Figure 3L ), indicating that tumor-associated mortality involves other processes than host energy regulation.
Since vn knockdown diminished tumor growth, systemic wasting effects were not observed in flies bearing yki 3SA tumors with vn RNAi (Figures 3K and 3L) . We further validated the autonomous effects of Pvr/MEK signaling by overexpressing an active form of Pvr (Pvr.l) in the host tissues. Consistently, Pvr gain of function in the fat body resulted in MEK activation, lipid loss, and trehalose elevation (Figures 4A-4C) , while in muscle, it potently caused climbing defects ( Figures 4D and 4E ). To mimic Pvf1 induction in yki 3SA -tumorbearing midgut, we further overexpressed Pvf1 in wild-type enterocytes and found MEK activation in both muscle and fat body and wasting effects, even though no obvious abdomen bloating was observed ( Figures 4F and 4G We previously showed that yki 3SA -tumor-derived ImpL2 contributes to host wasting (Kwon et al., 2015) . Thus, we wondered whether ImpL2 and Pvf1 are independent regulators. We first examined whether tumor-derived ImpL2 affects host MEK signaling and found that ImpL2 knockdown in yki 3SA tumors failed to suppress host pdERK ( Figure 4I ). In addition, MEK suppression does not impinge on tumor-derived ImpL2 to affect wasting, as administration of 10 mM Tram in flies bearing yki 3SA + dERK SEM tumors failed to affect tumor ImpL2 production, brain ILPs levels, as well as feeding behavior (Figures S3K-S3M ). Similarly, Pvf1 removal in yki 3SA -gut tumors also barely affected tumor ImpL2 production ( Figure S3N ). To examine a potential (J and K) Bloating and gut tumors (J) and wasting effects (K); including bloating rates (n = 3, 60 flies/group), TAG and trehalose levels (n = 3, 30 flies/group), as well as climbing speeds (n = 60) of flies bearing yki 3SA tumors with RNAi at day 10. UAS-Pvf1-RNAi-NIG7103R-1 and UAS-ImpL2-RNAi-VDRC30931 were used.
Data are presented as means ± SEM. *p < 0.05.
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DISCUSSION MEK/ERK Signaling Induces Muscle Wasting and Lipid Loss
Lipid loss and protein degradation-associated muscle wasting are two major features of tumor-induced host wasting in mammals (Fearon et al., 2013) . We observe similar outcomes in yki 3SA -tumor-bearing flies and show that the MEK/ERK pathway acts as a critical pathogenic factor. Although the molecular mechanisms of MEK action in fly are unknown, our results are reminiscent of some mammalian studies. For example, MEK signaling was found to regulate ubiquitination-associated proteolysis in mouse myotubes and promote lipid mobilization in mammalian adipocytes (Hong et al., 2018; Zheng et al., 2010) . We further confirmed similar MEK regulation in mammalian wasting models. Therefore, our study reveals that host MEK signaling plays a conserved role in tumor-induced wasting, including muscle wasting and lipid loss.
Ligand-Mediated Dual-MEK Regulation of Tumor-Host Interaction
The mechanism underlying the regulation of MEK signaling in tumor-induced host wasting is poorly understood. Here, we identified the secreted protein Pvf1 as a tumor-derived factor activating host MEK signaling. Pvr, the Pvf1 receptor, is expressed in both fat body and muscle (Kwon et al., 2015; Zheng et al., 2017) . Activation of Pvf/Pvr signaling by overexpressing an active form of Pvr in the muscle and fat body is sufficient to cause muscle wasting and lipid loss, respectively. Reducing Pvf1 production in yki 3SA -gut tumors decreased host MEK signaling and robustly alleviated wasting effects, while Pvf1 overexpression in wild-type midgut enterocytes somehow mimicked tumor-induced wasting effects, confirming that yki 3SA -gut tumor-derived Pvf1 non-autonomously promotes host MEK signaling and wasting. Note that as compared to pharmaceutical MEK inhibition in host tissues, Pvf1 removal from yki 3SA -gut tumors fails to prolong survival suggesting that systemic regulation of survival is more complicated than energy wasting in the context of tumor growth. We speculate that Pvf1/Pvr/MEK signaling is missing from some host tissues and that additional MEK-activating ligands produced either directly from yki 3SA tumors or indirectly in host tissues contribute to mortality. Autonomous MEK activation in yki 3SA -gut tumors is required for tumor growth. We demonstrate that only vn, a MEK-activating ligand essential for ISC proliferation , is critical for yki 3SA -gut tumor growth by activating Egfr/MEK signaling. Altogether, we propose a dual-MEK regulatory model whereby yki 3SA -gut tumors produce vn to autonomously promote selfgrowth, and Pvf1 to non-autonomously trigger Pvr/MEK signaling in host tissues and cause wasting ( Figure 4H ).
Organ Wasting Involves Energy Balance that Is Regulated by Multiple Tumor-Derived Ligands
We have previously shown that yki 3SA -gut tumors produce ImpL2 to suppress systemic insulin signaling and anabolism, which contribute to host wasting. However, ImpL2 removal from yki 3SA -gut tumors fails to completely abolish host wasting (Kwon et al., 2015) , suggesting the existence of other cachectic factor(s). Here, we demonstrate that yki 3SA -gut tumors also produce Pvf1 that remotely promotes MEK signaling and catabolism in host tissues and causes wasting. Further, removal of both ImpL2 and Pvf1 in yki 3SA -gut tumors exhibits additive improvement of host wasting, as compared to removal of either Impl2 or Pvf1. Thus, yki 3SA -gut tumors produce, at least, Pvf1 and ImpL2 to orchestrate organ wasting, involving both MEK and insulin signalingassociated catabolism and anabolism, respectively.
Interestingly, induction of these cachectic ligands is highly tumor-context dependent. Compared to yki 3SA , overexpression of a mild active form, yki S168A (Oh and Irvine, 2009) , in the ISCs only results in weak tumor growth, mild induction of Pvf1 and ImpL2, and slight host wasting (data not shown). In Ras V12 scrib À imaginal disc tumors (Figueroa-Clarevega and Bilder, 2015) , only ImpL2, but not Pvf1, is highly induced (data not shown). Our study also suggests other potential cachectic factors in yki 3SA tumors, as removal of other ligands than ImpL2 and Pvf1 diminished bloating as well ( Figure 3C ). As tumor-induced wasting is a complicated physiological process, it is not surprising to observe differential involvement of multiple ligands/regulators. Further studies will be needed to characterize the functions of tumor-derived ligands and the intricate cross-talks between them.
Relevance to MEK Cascade and Cancer Cachexia
In addition to flies and mouse cells, we also observed that Tram remarkably abolished MEK activation in host tissues and improved wasting in LLC-tumor-bearing mice (data not shown). However, we cannot conclude the beneficial effects from host MEK inhibition, as Tram also reduced tumor sizes by 50% (data now shown). Thus, we speculate that the inconsistent results of MEK inhibition (Au et al., 2016; Quan-Jun et al., 2017) might be caused by different tumor responses to MEK inhibitors. To address the impact of MEK inhibition in host tissues but not in tumors, we generated drug-resistant yki 3SA +dERK SEM -gut tumors in flies. Strikingly, MEK inhibitors, while no longer affecting tumor growth or tumor-derived ligand production, remarkably suppressed MEK signaling in host tissues (fat body, muscle, and maybe other secondary responsive organs) and abolished energy wasting. Thus, our results indicate that host MEK suppression is sufficient to reduce systemic wasting. Meanwhile, it will be worthy to obtain drug-resistant LLC cancer cells, via either random mutagenesis or genetic manipulation of MEK/ ERK pathway, and evaluate the effects of MEK inhibitors in mice bearing drug-resistant LLC tumors in the future.
Finally, our results provide genetic evidence of tumor-secreted proteins, rather than systemic inflammatory responses, in tumorinduced wasting. VEGF exists in mammals as a homolog of Drosophila Pvf1 and activates Ras/MEK signaling (Holmes and Zachary, 2005) . Similar to cachectic fly Pvf1, VEGF has been reported to be associated with lipid mobilization and muscle atrophy in mice (Gao et al., 2015; Sun et al., 2012) . Administration of antibodies against VEGF or VEGFR-2 elicits beneficial effects on multiple organs and prolongs survival of mice bearing high-VEGF tumors (Xue et al., 2008) . However, other tumor-derived ligands, including LIF and ILs, are also important MEK-activating factors and are associated with systemic catabolism (Miyamoto et al., 2016; Seto et al., 2015) . We therefore propose that cachectic tumors might produce multiple MEK-activating ligands to trigger organ wasting in mice and patients.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 40 ml of PBS, heated at 70 C for 5 min, and centrifuged at 14,000 rpm at 4 C for 10 min. 10 mL supernatant was treated with 0.2 ml trehalase (Megazyme, E-TREH) at 37 C for 30 min and then used to measure circulating trehalose levels with glucose assay reagent (Megazyme, K-GLUC). We subtracted the amount of free glucose in the supernatant from the measurement.
Lipolysis Measurements
For lipolysis measurement in flies, 10 adult abdomens containing fat bodies with midguts removed were dissected and washed with 1 mL M3 Insect Medium (Sigma, S8398) at room temperature. Supernatant was aspirated after a brief centrifugation and 10 abdomens were incubated with 100 mL M3 medium containing 4% fatty-acid-free BSA (w/v, Sigma, A7030-1KG) with or without 1 mM Trametinib for 1 hr at room temperature. Released glycerol in M3 medium was determined using Free Glycerol Reagent (Sigma, F6428-40ML). Abdomens were later lysed in RIPA buffer and used for protein quantification with Bradford Reagent (Sigma, B6916-500ML). Final lipolysis rate was calculated by normalizing released glycerol level to abdomen protein amount. For lipolysis measurement in adipocytes, after treated with control or conditioned medium 24 hr, 3T3-L1 adipocytes were washed with PBS and incubated with serum-and phenol-free DMEM containing 4% fatty-acid-free BSA with or without trametinib for 1 hr. The glycerol amount in the medium was immediately measured using a Free Glycerol Reagent kit (F6428, Sigma). After treated with conditioned medium and drugs for 24h, 3T3-L1 adipocytes were washed and harvested in TNET buffer (50 mM Tris-HCl (pH7.4), 150 mM NaCl, 2 mM EDTA, and 1% Triton X-100) with 0.5% cholate. Dissolved TAG was measured using a Serum Triglyceride Determination kit (TR0100, Sigma) and normalized to protein level.
Climbing Activity
Ten flies were placed in an empty vial and then tapped down to the bottom. They were allowed to climb for 3 s. Climbing was recorded and climbing height and speed were calculated from the video. A minimum of 60 flies and 10 separate trials were run per condition.
Immunostainings
Brains, midguts, and abdomens containing fat bodies were dissected in PBS and fixed for 15 min in PBS containing 4% paraformaldehyde. After fixation, the samples were washed with PBS containing 0.2% Triton X-100 (PBST) and blocked with 1% BSA in PBST for 30 min. After incubation with primary antibodies overnight at 4 C: p-ERK (1:100, Cell Signaling, 4370), Prospero (1:100, DSHB, MR1A), ILP2 (1:1000, a kind gift from Hugo Stocker), or Pvf1 (1:50, a kind gift from Ben-Zion Shilo). Tissues were washed and then incubated with secondary antibody and DAPI for 1 hr, washed, and mounted in Vectashield (Vector). C2C12 myoblasts were cultured and differentiated on cover slides. Treated C2C12 myotubes were washed and fixed for 15 min in PBS containing 4% formaldehyde. After fixation, the samples were washed with PBST, blocked with 1% BSA in PBST, and incubated with primary antibody against MHC (1:50, DSHB, MF20) overnight at 4 C. Cells were then incubated with secondary antibody and DAPI for 1h, washed and mounted in Vectashield (Vector). Treated 3T3-L1 mature adipocytes were incubated with Bodipy 493/503 (1 mg/mL, Life Technologies, D3922) for 20 min, washed, and imaged. Regular microscopy was performed on a Zeiss Axioskop 2motplus or a Nikon SMZ18 and confocal images were obtained using a Leica system. Western Blot 10 adult thoraces, 10 adult abdomens without midgut, and treated C2C12 myotubes and 3T3-L1 mature adipocytes were lysed in RIPA buffer containing inhibitors of proteases and phophatases. Extracts were immunoblotted with indicated antibodies: rabbit anti-ERK (1:1000, Cell Signaling, 4695), rabbit anti-phospho-ERK (1:1000, Cell Signaling, 4370), a-tubulin (1:5000, Sigma, T5168).
RNA-Seq Analysis of Adult Midgut 15 midguts of ctrl or yki 3SA flies incubated for 8 days at 29 C were dissected for total RNA extraction. After assessing RNA quality with Agilent Bioanalyzer (RIN > 7), total RNAs were sent to Columbia Genome Center for RNA-seq analysis following the standard protocol. Briefly, mRNAs were enriched by poly-A pull-down. Sequencing libraries were prepared with Illumina Truseq RNA preparation kit and were sequenced using Illumina HiSeq 2000. Samples were multiplexed in each lane, which yields target number of single-end 100-bp reads for each sample, as a fraction of 180 million reads for the whole lane. The RNA-seq data were deposited in the Gene Expression Omnibus (accession number GSE113728). After trimming, sequence reads were mapped to the Drosophila genome (FlyBase genome annotation version r6.15) using Tophat. With the uniquely mapped reads, gene expression was quantified using Cufflinks (FPKM values) and HTseq (read counts per gene). Differentially expressed genes were analyzed based on both adjusted P value using DSeq2 as well as fold change cut-off. Prior to fold change calculation, we set to a value of ''1'' for any FPKM value between 0 and 1 to reduce the possibility that we get large ratio values for genes with negligible levels of detected transcript in both experimental and control samples (e.g. FPKM 0.1 vs. 0.0001), as those ratios are unlikely to have biological relevance. A cut-off of 2-fold change consistently observed among replicates and the adjusted P value of 0.05 or lower from DSeq2 analysis were used as criteria to define the set of 552 down-regulated and 1659 up-regulated genes. Heatmap was generated using MEV_4_7 based on FPKM changes. qPCR 10 adult midguts or heads of each genotype and C2C12 myotubes were lysed with Trizol for RNA extraction and cDNA transcribed using the iScript cDNA Synthesis Kit (Bio-rad). qPCR was then performed using iQ SYBR Green Supermix on a CFX96 Real-Time
